• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Expert: UGN-102 has potential to change practice in LG-IR NMIBC

News
Video

“I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing,” says Sandip M. Prasad, MD, MPhil.

In this video, Sandip M. Prasad, MD, MPhil, gives his final thoughts on the recent Journal of Urology paper, “Treatment of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer with UGN-102 ± Transurethral Resection of Bladder Tumor (TURBT) Compared to TURBT Monotherapy: A Randomized, Controlled, Phase 3 Trial (ATLAS).” Prasad is a urologist with Garden State Urology in Morristown, New Jersey.

Transcription:

Is there anything you would like to add?

I think this is a very interesting study for urologists as a whole, because there are not many surgical trials that we do. It's a very hard thing to enroll patients into surgical trials. So here, we were actually able to achieve that with randomization, which again, for someone who's been in urology for almost 20 years, surgical trials often don't fill because patients are really reticent to go through a trial that randomizes you to surgery or not surgery. That's a hard decision to leave to the flip of a coin. So I really credit the other study investigators for being able to put patients on study, demonstrating that there's importance for this kind of research. I applaud those other investigators who have been able to enroll patients in a study like this, because in the end, we may have achieved a really paradigm-shifting surgical and medical treatment approach for bladder cancer, which again, is the bread and butter of almost every urology practice. That's the other part of this that's really exciting. It's fun to be part of something that really affects every single urologist from single practitioners in small rural communities, to large academic centers. We're all doing TURBTs; we're all seeing low-grade intermediate-risk bladder cancer. This is an extremely common problem, with tens of thousands of patients that we see a year with this condition who continue to recur over time. And so again, I think it's extremely exciting to be part of something that is possibly practice changing, potentially field changing, and I'm really excited to see what the data from ENVISION show.

This transcript was edited for clarity.

Related Videos
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Zhina Sadeghi, MD, answers a question during a video interview
A panel of 5 experts on bladder cancer
A panel of 5 experts on bladder cancer
Stephanie Gleicher, MD, answers a question during a Zoom video interview
Human kidney cross section on scientific background | © Crystal light - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.